The FDA is proposing to remove weight-loss drugs made by Novo Nordisk and Eli Lilly from a list of medicines that pharmacies can copy and make in bulk. This would be good for the companies because it would force more patients to buy their brand-name versions instead of cheaper pharmacy-made copies.

• •FDA proposes excluding Novo and Lilly weight-loss drugs from bulk compounding list
• •Move would restrict pharmacies from making bulk copies of the drugs
• •Patients would be pushed toward brand-name versions

Health Canada approved the first generic version of semaglutide (Ozempic), Novo Nordisk's popular diabetes and weight-loss drug. This means Canadian patients may soon have access to a cheaper alternative to the brand-name version.

• •Health Canada approved the first generic version of Ozempic (semaglutide).
• •Approval covers Novo Nordisk's diabetes and weight-loss drug.
• •Canadian patients may gain access to a cheaper alternative to the brand.

Novo Nordisk is lowering the advertised U.S. prices for Ozempic (a diabetes drug) and Wegovy (a weight-loss drug) by as much as 50%. This is the company's move to make these expensive medications more affordable for patients and insurers.

• •Novo Nordisk to cut US list prices for Ozempic and Wegovy by up to 50%
• •Move targets affordability for patients and insurers

The FDA is proposing new rules to limit pharmacies from making large quantities of generic copies of Novo Nordisk and Eli Lilly's weight-loss drugs. This could force patients to buy the more expensive brand-name versions instead of cheaper pharmacy-made alternatives.

• •FDA proposing rules to curb mass compounding of Novo and Lilly weight-loss drugs
• •Patients may be pushed toward more expensive brand-name versions
• •Targets pharmacy-made generic copies of GLP-1 weight-loss drugs

The FDA is proposing new rules to limit how much pharmacies can make generic copies of Novo Nordisk and Eli Lilly's weight-loss drugs. This could force more patients to buy the expensive brand-name versions instead of cheaper alternatives.

• •FDA proposing rules to limit pharmacy compounding of Novo and Lilly weight-loss drugs
• •Move could redirect patients to brand-name versions
• •Targets mass compounding of GLP-1 copies

The FDA is proposing to block pharmacies from making cheaper copies of GLP-1 weight-loss drugs, which would help Eli Lilly and Novo Nordisk sell more of their brand-name versions. This rule change could force patients to buy the expensive official medicines instead of lower-cost pharmacy-made alternatives.

• •FDA proposing to block pharmacies from compounding GLP-1 weight-loss drugs
• •Rule would favor branded versions from Eli Lilly and Novo Nordisk
• •Patients would lose access to lower-cost pharmacy-made alternatives

The FDA is taking steps to permanently ban pharmacies from making compounded versions of GLP-1 drugs (weight-loss and diabetes medications like semaglutide). This could force patients to buy more expensive brand-name versions instead of cheaper pharmacy-made copies.

• •FDA moving to permanently bar pharmacies from compounding GLP-1 drugs
• •Action targets compounded versions of semaglutide and related GLP-1s
• •Patients would be pushed toward more expensive brand-name products

Canada approved a generic version of semaglutide (the active ingredient in Ozempic) made by Dr. Reddy's Laboratories. This generic copy is cheaper and could give more people access to the weight-loss and diabetes drug.

• •Canada approved Dr. Reddy's generic version of semaglutide
• •Semaglutide is the active ingredient in Novo Nordisk's Ozempic
• •Generic is cheaper and aims to broaden access for diabetes and weight loss

Canada's health regulator approved a second generic copy of semaglutide (Ozempic), the popular diabetes and weight-loss drug made by Novo Nordisk. More generic options could help lower costs for patients in Canada.

• •Canada's health regulator approved a second generic version of semaglutide (Ozempic)
• •Ozempic is made by Novo Nordisk
• •More generic options could help lower costs for patients in Canada

Canada approved a second generic version of Ozempic (a semaglutide injection used for diabetes and weight loss). This expands access to cheaper copies of the drug beyond Novo Nordisk's brand-name version.

• •Canada approved a second generic version of Ozempic (semaglutide injection)
• •Generic is indicated for diabetes and weight loss
• •Approval adds a second copycat competing with Novo Nordisk's brand

Novo Nordisk's oral form of Ozempic (a GLP-1 peptide drug for type 2 diabetes) has FDA approval and will soon be available in the United States. This is the first FDA-approved pill version of a GLP-1 peptide medication for adults with type 2 diabetes.

• •FDA approved Novo Nordisk's oral Ozempic for adults with type 2 diabetes
• •Positioned as the only FDA-approved oral peptide GLP-1 for T2D
• •US launch imminent per Novo Nordisk

Novo Nordisk's oral version of Ozempic (a GLP-1 peptide drug used for type 2 diabetes) will become available in the United States soon. This is the only FDA-approved pill form of this type of medication for adults with diabetes.

• •Novo Nordisk's oral Ozempic to become available in the US soon
• •Only FDA-approved oral peptide GLP-1 for adults with type 2 diabetes

Novo Nordisk and Eli Lilly are proposing that their drugs be removed from a U.S. list that allows pharmacies to make cheaper copies. The change would make it harder for compounding pharmacies to create generic versions and could force more patients to buy the expensive brand-name drugs instead.

• •Novo Nordisk and Eli Lilly proposing removal of their drugs from a key US list
• •Change would restrict compounding pharmacies from making cheaper copies
• •Patients could be pushed toward brand-name versions

Novo Nordisk is making Ozempic tablets (semaglutide) available across the United States starting May 4. This is a pill version of the weight-loss and diabetes drug that was previously only available as an injection.

• •Novo Nordisk to make Ozempic tablets (semaglutide) available across the US starting May 4
• •Pill version of a drug previously available only as an injection

The FDA is taking action against bulk production of obesity drug ingredients, which helped stock prices rise for Eli Lilly and Novo Nordisk. This move could benefit the companies by reducing competition from cheaper, bulk-made versions of weight-loss medicines.

• •FDA moving against bulk production of obesity drug ingredients
• •Eli Lilly and Novo Nordisk shares rose on the news

A generic version of Novo Nordisk's GLP-1 drug has become available in Canada. Industry observers see this as an important test case for how generic GLP-1 drugs will compete with brand-name versions worldwide.

• •Generic of Novo Nordisk's GLP-1 drug has become available in Canada
• •Observers frame the launch as a test case for global generic GLP-1 competition

• •Novo Nordisk's oral Ozempic referenced as arriving to market

Novo Nordisk's oral version of Ozempic (semaglutide) is becoming available at pharmacies. The company is reporting earnings this week, and investors are watching closely to see how well the pill form performs.

• •Novo Nordisk's oral version of Ozempic (semaglutide) is reaching pharmacies
• •Novo Nordisk reports earnings this week
• •Investor focus is on early performance of the oral format

• •Novo Nordisk is rebranding its diabetes pill under the Ozempic name

Novo Nordisk is giving its diabetes pill a new name in the United States—it will now be called Ozempic, the same name as the company's popular injectable weight-loss drug. This name change helps patients and doctors recognize that both the pill and injection contain the same active ingredient (semaglutide) and work the same way.

• •Novo Nordisk rebranding its oral diabetes tablet as Ozempic in the US
• •Pill and injection share semaglutide as active ingredient

Novo Nordisk is preparing to launch an oral (pill) version of Ozempic, its semaglutide diabetes drug, in the United States. This expands the company's options beyond the injectable form already available to American patients.

• •Novo Nordisk is preparing a US launch of an oral version of Ozempic
• •Oral formulation uses semaglutide, same molecule as injectable Ozempic
• •Expands Novo's US options beyond the existing injectable form

• •Novo Nordisk is rebranding its oral semaglutide diabetes pill under the Ozempic name

Novo Nordisk has stopped selling Rybelsus, its oral semaglutide tablet, in the United States and is now calling semaglutide pills by the Ozempic brand name instead. This change makes the pill version match the name of the popular injection form.

• •Novo Nordisk has retired the Rybelsus brand in the US
• •Oral semaglutide will now be marketed under the Ozempic name
• •Move unifies pill and injection under a single brand

Eli Lilly says its new oral weight-loss pill Foundayo is off to a good start, but early signs suggest it may not be selling as well as Novo Nordisk's similar pill. Both companies are competing to win patients who want to take a weight-loss drug by mouth instead of injections.

• •Lilly described Foundayo's obesity launch as 'encouraging' in early days
• •Foundayo appears to be lagging Novo Nordisk's competing GLP-1 pill
• •Both companies targeting patients seeking oral alternatives to injectables

Boehringer Ingelheim and Zealand Pharma's obesity drug showed results in a Phase 3 trial (a late-stage test) that resembled Novo Nordisk's Wegovy (a popular weight-loss medicine). The comparison suggests the drug may be competitive in the weight-loss market.

• •Boehringer/Zealand obesity drug posted Phase 3 results compared to Novo's Wegovy
• •Trial profile described as 'more akin' to Wegovy

• •Lilly and Novo Nordisk shares dipped on the news
• •A proposed Medicare coverage pilot for GLP-1s has been thrown off balance

A study found that Wegovy (semaglutide), a weight-loss shot made by Novo Nordisk, helped people with alcohol addiction drink less. The finding suggests the drug might work for reducing drinking in addition to its approved uses for weight loss and diabetes.

• •Study found Wegovy (semaglutide) helped people with alcohol addiction drink less
• •Wegovy is made by Novo Nordisk and approved for weight loss and diabetes